WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406356
Description: KR30031 is a novel P-glycoprotein inhibitor with potential anticancer activity. KR30031 is a verapamil analog with fewer cardiovascular effects. The ability of KR-30031 to reduce this efflux transport is equal to that of verapamil, a well-known P-glycoprotein inhibitor. The bioavailability of paclitaxel could be enhanced by coadministration of a P-glycoprotein inhibitor, KR-30031.
MedKoo Cat#: 406356
Chemical Formula: C26H34N2O4
Exact Mass: 438.25186
Molecular Weight: 438.56
Elemental Analysis: C, 71.21; H, 7.81; N, 6.39; O, 14.59
Synonym: KR30031; KR-30031; KR 30031.
IUPAC/Chemical Name: 1-(3-((3,4-dimethoxyphenethyl)(methyl)amino)propyl)-4,5-dimethoxy-2,3-dihydro-1H-indene-1-carbonitrile
InChi Key: VLSLFQMGJUJBQJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H34N2O4/c1-28(16-12-19-7-9-22(29-2)24(17-19)31-4)15-6-13-26(18-27)14-11-20-21(26)8-10-23(30-3)25(20)32-5/h7-10,17H,6,11-16H2,1-5H3
SMILES Code: N#CC1(CCCN(CCC2=CC=C(OC)C(OC)=C2)C)CCC3=C1C=CC(OC)=C3OC
Appearance: white to off-white solid powder.
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs
Storage Condition: 0 – 4 C for short term (weeks to 1 month) or -20 C for long terms (months to years).
Solubility: soluble in DMSO, not soluble in water
Shelf Life: >2 years if stored properly.
Drug Formulation: this drug may be formulated in DMSO.
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 438.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Werle M. Polymeric and low molecular mass efflux pump inhibitors for oral drug delivery. J Pharm Sci. 2008 Jan;97(1):60-70. Review. PubMed PMID: 17721883.
2: Kim DW, Kwon JS, Kim YG, Kim MS, Lee GS, Youn TJ, Cho MC. Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. Circulation. 2004 Mar 30;109(12):1558-63. Epub 2004 Mar 8. PubMed PMID: 15006998.
3: Woo JS, Lee CH, Shim CK, Hwang SJ. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res. 2003 Jan;20(1):24-30. PubMed PMID: 12608532.
4: Lee BH, Lee CO, Kwon MJ, Yi KY, Yoo SE, Choi SU. Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity. Anticancer Drugs. 2003 Feb;14(2):175-81. PubMed PMID: 12569305.